Your browser doesn't support javascript.
loading
Potential cardioprotective and anticancer effects of carvedilol either free or as loaded nanoparticles with or without doxorubicin in solid Ehrlich carcinoma-bearing mice.
Zidan, Amr; El Saadany, Amira A; El Maghraby, Gamal M; Abdin, Amany A; Hedya, Sabeha E.
Afiliação
  • Zidan A; Department of Pharmacology, Faculty of Medicine, Tanta University, Egypt. Electronic address: amr.zeidan@med.tanta.edu.eg.
  • El Saadany AA; Department of Pharmacology, Faculty of Medicine, Tanta University, Egypt.
  • El Maghraby GM; Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Egypt.
  • Abdin AA; Department of Pharmacology, Faculty of Medicine, Tanta University, Egypt.
  • Hedya SE; Department of Pharmacology, Faculty of Medicine, Tanta University, Egypt.
Toxicol Appl Pharmacol ; 465: 116448, 2023 04 15.
Article em En | MEDLINE | ID: mdl-36921847
AIM: The aim of this study was to investigate the potential cardioprotective and anti-cancer effects of carvedilol (CAR) either free or as loaded nano-formulated with or without doxorubicin (DOX) in solid Ehrlich carcinoma (SEC)-bearing mice. It focused on assessment of cardiac damage, drug resistance, apoptosis, oxidative stress status, angiogenesis and proliferation. METHODS: CAR was loaded into poly-D,L lactic-co-glycolic acid)PLGA(or Niosomes. SEC was induced in female albino mice as an experimental model of breast cancer. Seventy-two mice were randomly divided into 9 equal groups (Normal control, Untreated-SEC, SEC + DOX, SEC + CAR-free, SEC + CAR-PLGA, SEC + CAR-Niosomes, SEC + DOX + CAR-free, SEC + DOX + CAR-PLGA and SEC + DOX + CAR-Niosomes). Tumor volume and survival rate were recorded. On day 28 from tumor inoculation, mice were sacrificed, and blood samples were collected for determination of serum lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB). One part from tumor tissues was prepared for assessment of multidrug resistance protein-1 (MDR-1), caspase-3, reduced glutathione (GSH) and malondialdehyde (MDA), while the other part was processed for histopathological examination and immunohistochemical expression of vascular endothelial growth factor (VEGF) and Ki-67. RESULTS: There was non-significant difference between CAR-free, CAR-PLGA and CAR-Niosomes as anticancer either alone or when combined with DOX. However, CAR-free demonstrated potential cardioprotective effects against cardiac damage mediated by cancer or DOX that have been enhanced using CAR-PLGA or CAR-Niosomes, but that of Niosomes outperformed them both. CONCLUSION: CAR could be used as an adjuvant therapy with DOX, especially when nanoformualted with PLGA and even better with Niosomes, without compromising its cytotoxicity against cancer cells and preventing its cardiotoxic impacts.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Nanopartículas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Toxicol Appl Pharmacol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Nanopartículas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Toxicol Appl Pharmacol Ano de publicação: 2023 Tipo de documento: Article